VRTX Vertex Pharmaceuticals
Nasdaq · SEC CIK 875320 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $158.38M 53 sales by 13 insiders
- Filings on record
- 531 since 2021-07-16, latest 2026-09-10 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| Bozic Carmen | EVP, CMO | — | $11.31M |
| WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| Biller Jonathan | EVP, CLO | — | $4.08M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 621
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-08-10 | 2022-08-08 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $293.03 | -621 | 4,661 | -12% | -$182.0K |
| DM | 2022-08-10 | 2022-08-09 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $300.67 | -5,690 | 61.9K | -8% | -$1.71M |
| D | 2022-08-10 | 2022-08-09 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +1,926 | 66.7K | +3% | +$299.6K |
| M | 2022-08-10 | 2022-08-09 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.97 | -1,400 | 47.2K | -3% | -$418.6K |
| DM | 2022-08-10 | 2022-08-08 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $292.54 | -1,304 | 36.5K | -3% | -$381.5K |
| D | 2022-08-10 | 2022-08-08 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $187.53 | +1,304 | 37.4K | +4% | +$244.5K |
| 2022-08-03 | 2022-08-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $276.62 | -766 | 41.0K | -2% | -$211.9K | |
| M | 2022-08-02 | 2022-07-29 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $278.77 | -621 | 5,604 | -10% | -$173.1K |
| DM | 2022-07-27 | 2022-07-25 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale+OE | $281.38 | -132.1K | 2,423 | -98% | -$37.16M |
| D | 2022-07-27 | 2022-07-25 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | M - OptEx | $91.05 | +60.3K | 134.5K | +81% | +$5.49M |
| DM | 2022-07-21 | 2022-07-19 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $288.65 | -17.9K | 53.0K | -25% | -$5.16M |
| DM | 2022-07-21 | 2022-07-19 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $174.33 | +17.8K | 53.9K | +49% | +$3.10M |
| 2022-06-28 | 2022-06-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $291.30 | -11.7K | 111.2K | -10% | -$3.41M | |
| 2022-06-02 | 2022-05-31 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $271.24 | -311 | 49.5K | -0.6% | -$84.4K | |
| 2022-05-19 | 2022-05-18 | VRTX | Upadhyay Suketu | Dir | A - Grant | $0.00 | +1,558 | 1,558 | New | $0 | |
| M | 2022-05-18 | 2022-05-16 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $251.19 | -133 | 64.9K | -0.2% | -$33.4K |
| M | 2022-05-18 | 2022-05-16 | VRTX | Liu Joy | SVP, GC | S - Sale | $252.88 | -133 | 14.4K | -0.9% | -$33.6K |
| M | 2022-05-18 | 2022-05-16 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $252.83 | -45 | 41.7K | -0.1% | -$11.4K |
| 2022-05-06 | 2022-05-04 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $275.09 | -36 | 41.7K | -0.1% | -$9,903 | |
| M | 2022-05-04 | 2022-05-02 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $258.83 | -343 | 43.0K | -0.8% | -$88.8K |
| M | 2022-05-04 | 2022-05-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $259.16 | -320 | 41.9K | -0.8% | -$82.9K |
| M | 2022-05-04 | 2022-05-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $258.94 | -737 | 6,320 | -10% | -$190.8K |
| 2022-05-04 | 2022-05-02 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $263.98 | -306 | 64.8K | -0.5% | -$80.8K | |
| 2022-05-03 | 2022-05-01 | VRTX | CARNEY LLOYD | Dir | A - Grant | $0.00 | +1,449 | 6,850 | +27% | $0 | |
| M | 2022-05-03 | 2022-04-29 | VRTX | Liu Joy | SVP, GC | S - Sale | $275.41 | -120 | 14.3K | -0.8% | -$33.0K |
| 2022-05-03 | 2022-04-29 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $276.17 | -547 | 43.1K | -1% | -$151.1K | |
| D | 2022-05-03 | 2022-05-01 | VRTX | MCGLYNN MARGARET G | Dir | D - Sale to Iss | — | -921 | 178 | -84% | — |
| D | 2022-05-03 | 2022-05-01 | VRTX | MCKENZIE DIANA | Dir | A - Grant | $0.00 | +1,449 | 2,884 | +101% | $0 |
| D | 2022-05-03 | 2022-05-01 | VRTX | MCKENZIE DIANA | Dir | D - Sale to Iss | — | -1,842 | 1,435 | -56% | — |
| 2022-05-03 | 2022-04-29 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $276.17 | -766 | 42.0K | -2% | -$211.5K | |
| 2022-05-03 | 2022-05-01 | VRTX | Bhatia Sangeeta N. | Dir | A - Grant | $0.00 | +1,449 | 6,640 | +28% | $0 | |
| D | 2022-05-03 | 2022-05-01 | VRTX | Kearney Terrence C | Dir | A - Grant | $0.00 | +725 | 6,536 | +12% | $0 |
| M | 2022-04-27 | 2022-04-25 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $269.55 | -327 | 3,600 | -8% | -$88.1K |
| D | 2022-04-20 | 2022-04-18 | VRTX | Lee Yuchun | Dir | M - OptEx | $81.54 | +2,000 | 3,875 | +107% | +$163.1K |
| DM | 2022-04-20 | 2022-04-18 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $284.23 | -2,000 | 3,493 | -36% | -$568.5K |
| DM | 2022-04-18 | 2022-04-14 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $289.06 | -2,000 | 2,675 | -43% | -$578.1K |
| D | 2022-04-18 | 2022-04-14 | VRTX | Lee Yuchun | Dir | M - OptEx | $81.54 | +2,000 | 3,875 | +107% | +$163.1K |
| 2022-04-14 | 2022-04-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $289.04 | -15.8K | 74.2K | -18% | -$4.56M | |
| DM | 2022-04-14 | 2022-04-12+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $284.27 | -4,000 | 3,029 | -57% | -$1.14M |
| DM | 2022-04-14 | 2022-04-12+ | VRTX | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| DM | 2022-04-12 | 2022-04-08 | VRTX | MCGLYNN MARGARET G | Dir | S - Sale+OE | $280.22 | -5,000 | 1,099 | -82% | -$1.40M |
| D | 2022-04-12 | 2022-04-08 | VRTX | MCGLYNN MARGARET G | Dir | M - OptEx | $127.54 | +5,000 | 6,099 | +455% | +$637.7K |
| D | 2022-04-12 | 2022-04-08 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale+OE | $280.20 | -1,907 | 5,191 | -27% | -$534.3K |
| D | 2022-04-12 | 2022-04-08 | VRTX | Bhatia Sangeeta N. | Dir | M - OptEx | $125.71 | +1,907 | 7,098 | +37% | +$239.7K |
| DM | 2022-04-12 | 2022-04-08+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $279.43 | -4,000 | 3,027 | -57% | -$1.12M |
| DM | 2022-04-12 | 2022-04-08+ | VRTX | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| DM | 2022-04-08 | 2022-04-06+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $273.24 | -4,000 | 3,858 | -51% | -$1.09M |
| DM | 2022-04-08 | 2022-04-06+ | VRTX | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| M | 2022-04-08 | 2022-04-07 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $276.18 | -561 | 42.8K | -1% | -$154.9K |
| DM | 2022-04-06 | 2022-04-04+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $270.11 | -4,000 | 1,875 | -68% | -$1.08M |
| DM | 2022-04-06 | 2022-04-04+ | VRTX | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| M | 2022-04-06 | 2022-04-04+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $274.10 | -3,725 | 46.8K | -7% | -$1.02M |
| 2022-04-05 | 2022-04-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $263.09 | -1,344 | 47.1K | -3% | -$353.6K | |
| M | 2022-04-05 | 2022-04-01 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $264.76 | -2,582 | 43.8K | -6% | -$683.6K |
| 2022-04-05 | 2022-04-01 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $263.09 | -137 | 3,823 | -3% | -$36.0K | |
| D | 2022-04-04 | 2022-03-31 | VRTX | MCGLYNN MARGARET G | Dir | M - OptEx | $127.54 | +5,000 | 6,099 | +455% | +$637.7K |
| DM | 2022-04-04 | 2022-03-31 | VRTX | MCGLYNN MARGARET G | Dir | S - Sale+OE | $262.27 | -5,000 | 5,080 | -50% | -$1.31M |
| M | 2022-03-21 | 2022-03-17 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $250.15 | -3,171 | 46.3K | -6% | -$793.2K |
| M | 2022-03-21 | 2022-03-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $250.11 | -2,833 | 47.4K | -6% | -$708.6K |
| 2022-03-21 | 2022-03-17 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.06 | -2,122 | 48.4K | -4% | -$530.6K | |
| 2022-02-28 | 2022-02-24 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $227.86 | -1,242 | 49.8K | -2% | -$283.0K | |
| 2022-02-28 | 2022-02-24 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $227.86 | -7,246 | 65.1K | -10% | -$1.65M | |
| 2022-02-28 | 2022-02-24 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $227.86 | -2,189 | 49.4K | -4% | -$498.8K | |
| 2022-02-28 | 2022-02-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $227.86 | -7,246 | 122.8K | -6% | -$1.65M | |
| 2022-02-28 | 2022-02-24 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $227.86 | -12.1K | 89.9K | -12% | -$2.77M | |
| 2022-02-28 | 2022-02-24 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $227.86 | -6,038 | 43.6K | -12% | -$1.38M | |
| M | 2022-02-28 | 2022-02-25 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $230.98 | -7,572 | 42.6K | -15% | -$1.75M |
| M | 2022-02-28 | 2022-02-25 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $230.95 | -325 | 50.3K | -0.6% | -$75.1K |
| 2022-02-28 | 2022-02-24 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $227.86 | -2,590 | 50.5K | -5% | -$590.2K | |
| 2022-02-28 | 2022-02-24 | VRTX | Liu Joy | SVP, GC | F - Tax | $227.86 | -1,554 | 14.5K | -10% | -$354.1K | |
| 2022-02-28 | 2022-02-24 | VRTX | Sachdev Amit | EVP, Chief Patient Off | F - Tax | $227.86 | -7,368 | 48.2K | -13% | -$1.68M | |
| 2022-02-22 | 2022-02-17 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $232.51 | -8,584 | 130.1K | -6% | -$2.00M | |
| 2022-02-22 | 2022-02-17 | VRTX | Liu Joy | SVP, GC | F - Tax | $232.51 | -712 | 16.0K | -4% | -$165.5K | |
| M | 2022-02-22 | 2022-02-18 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $231.00 | -519 | 53.3K | -1.0% | -$119.9K |
| 2022-02-22 | 2022-02-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $232.51 | -4,114 | 53.6K | -7% | -$956.5K | |
| 2022-02-22 | 2022-02-17 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $232.51 | -3,439 | 51.1K | -6% | -$799.6K | |
| 2022-02-22 | 2022-02-17 | VRTX | Sachdev Amit | EVP, Chief Patient Off | F - Tax | $232.51 | -3,497 | 55.6K | -6% | -$813.1K | |
| 2022-02-22 | 2022-02-17 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $232.51 | -8,236 | 102.1K | -7% | -$1.91M | |
| 2022-02-22 | 2022-02-17 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $232.51 | -3,439 | 54.0K | -6% | -$799.6K | |
| M | 2022-02-22 | 2022-02-18 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $230.97 | -4,312 | 53.0K | -8% | -$995.9K |
| 2022-02-22 | 2022-02-17 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $232.51 | -3,439 | 51.6K | -6% | -$799.6K | |
| 2022-02-22 | 2022-02-17 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $232.51 | -4,126 | 72.3K | -5% | -$959.3K | |
| 2022-02-22 | 2022-02-17 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $232.51 | -3,439 | 50.5K | -6% | -$799.6K | |
| 2022-02-16 | 2022-02-14 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $232.02 | -2,444 | 57.4K | -4% | -$567.1K | |
| 2022-02-14 | 2022-02-10 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $237.74 | -1,230 | 58.0K | -2% | -$292.4K | |
| M | 2022-02-14 | 2022-02-11 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $235.09 | -290 | 57.7K | -0.5% | -$68.2K |
| 2022-02-14 | 2022-02-10 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $237.74 | -2,437 | 54.5K | -4% | -$579.4K | |
| 2022-02-14 | 2022-02-10 | VRTX | Sachdev Amit | EVP, Chief Patient Off | F - Tax | $237.74 | -2,491 | 59.1K | -4% | -$592.2K | |
| 2022-02-14 | 2022-02-10 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $237.74 | -2,434 | 55.0K | -4% | -$578.7K | |
| 2022-02-14 | 2022-02-10 | VRTX | Liu Joy | SVP, GC | F - Tax | $237.74 | -474 | 16.7K | -3% | -$112.7K | |
| 2022-02-14 | 2022-02-10 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $237.74 | -3,518 | 62.2K | -5% | -$836.4K | |
| M | 2022-02-14 | 2022-02-11 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $235.02 | -2,297 | 59.9K | -4% | -$539.8K |
| 2022-02-14 | 2022-02-10 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $237.74 | -979 | 54.0K | -2% | -$232.7K | |
| 2022-02-14 | 2022-02-10 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $237.74 | -3,031 | 138.7K | -2% | -$720.6K | |
| 2022-02-14 | 2022-02-10 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $237.74 | -3,040 | 76.4K | -4% | -$722.7K | |
| 2022-02-03 | 2022-02-02 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $250.07 | -2,944 | 57.4K | -5% | -$736.2K | |
| M | 2022-02-03 | 2022-02-01 | VRTX | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +25.6K | 50.1K | +104% | $0 |
| M | 2022-02-03 | 2022-02-01 | VRTX | Liu Joy | SVP, GC | A - Grant | $0.00 | +8,941 | 17.2K | +108% | $0 |
| M | 2022-02-03 | 2022-02-01 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +67.9K | 112.6K | +152% | $0 |
| M | 2022-02-03 | 2022-02-01 | VRTX | Sachdev Amit | EVP, Chief Patient Off | A - Grant | $0.00 | +29.6K | 41.7K | +245% | $0 |
Purchase Sale Sale after option exercise All abbreviations